171 related articles for article (PubMed ID: 34461181)
1. Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer.
Gu Z; Du Y; Zhao X; Wang C
Cancer Lett; 2021 Aug; 521():98-108. PubMed ID: 34461181
[TBL] [Abstract][Full Text] [Related]
2. A new era: tumor microenvironment in chemoresistance of pancreatic cancer.
Zhao X; Li Z; Gu Z
J Cancer Sci Clin Ther; 2022; 6(1):61-86. PubMed ID: 35187493
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
[TBL] [Abstract][Full Text] [Related]
4. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
[TBL] [Abstract][Full Text] [Related]
5. Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going.
Liang C; Shi S; Meng Q; Liang D; Ji S; Zhang B; Qin Y; Xu J; Ni Q; Yu X
Exp Mol Med; 2017 Dec; 49(12):e406. PubMed ID: 29611542
[TBL] [Abstract][Full Text] [Related]
6. Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma.
Okuno K; Xu C; Pascual-Sabater S; Tokunaga M; Takayama T; Han H; Fillat C; Kinugasa Y; Goel A
Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672630
[TBL] [Abstract][Full Text] [Related]
7. Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency.
Chen D; Zhu X; Tao W; Kong Y; Huag Y; Zhang Y; Liu R; Jiang L; Tang Y; Yu H; Hao Q; Yang X; Zou H; Chen J; Lu Y; Zhang H; Li W
J Control Release; 2020 Aug; 324():545-559. PubMed ID: 32504777
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells.
Huang B; Wang J; Chen Q; Qu C; Zhang J; Chen E; Zhang Y; Wang Y; Ni L; Liang T
Am J Transl Res; 2019; 11(1):473-485. PubMed ID: 30788003
[TBL] [Abstract][Full Text] [Related]
9. OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma.
Ding J; Li H; Liu Y; Xie Y; Yu J; Sun H; Xiao D; Zhou Y; Bao L; Wang H; Gao C
Front Oncol; 2021; 11():698302. PubMed ID: 34804914
[TBL] [Abstract][Full Text] [Related]
10. Stellate Cells Aid Growth-Permissive Metabolic Reprogramming and Promote Gemcitabine Chemoresistance in Pancreatic Cancer.
Amrutkar M; Gladhaug IP
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546284
[TBL] [Abstract][Full Text] [Related]
11. Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma.
Okuno K; Xu C; Pascual-Sabater S; Tokunaga M; Han H; Fillat C; Kinugasa Y; Goel A
Pharmaceuticals (Basel); 2022 Sep; 15(10):. PubMed ID: 36297310
[TBL] [Abstract][Full Text] [Related]
12. A tumor microenvironment-stimuli responsive nano-prodrug for overcoming gemcitabine chemoresistance by co-delivered miRNA-21 modulator.
Zhang F; Yao Z; Jin P; Xu M; Hu Q; Chen Y; Que R; Liang T
Biomed Mater; 2023 Apr; 18(3):. PubMed ID: 36990101
[TBL] [Abstract][Full Text] [Related]
13. Microfluidic-Assisted Preparation of Targeted pH-Responsive Polymeric Micelles Improves Gemcitabine Effectiveness in PDAC: In Vitro Insights.
Iacobazzi RM; Arduino I; Di Fonte R; Lopedota AA; Serratì S; Racaniello G; Bruno V; Laquintana V; Lee BC; Silvestris N; Leonetti F; Denora N; Porcelli L; Azzariti A
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008170
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies.
Natu J; Nagaraju GP
Cancer Lett; 2023 Oct; 573():216382. PubMed ID: 37666293
[TBL] [Abstract][Full Text] [Related]
15. A biomimetic nanodrug for enhanced chemotherapy of pancreatic tumors.
Zhang F; Hu Q; Li B; Huang Y; Wang M; Shao S; Tang H; Yao Z; Ping Y; Liang T
J Control Release; 2023 Feb; 354():835-850. PubMed ID: 36627026
[TBL] [Abstract][Full Text] [Related]
16. ENO1 silencing impaires hypoxia-induced gemcitabine chemoresistance associated with redox modulation in pancreatic cancer cells.
Wang L; Bi R; Yin H; Liu H; Li L
Am J Transl Res; 2019; 11(7):4470-4480. PubMed ID: 31396350
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugs.
Zhao B; Qin C; Li Z; Wang Y; Li T; Cao H; Yang X; Li T; Wang W
Cancer Cell Int; 2022 Dec; 22(1):374. PubMed ID: 36457017
[TBL] [Abstract][Full Text] [Related]
18. Heme Oxygenase-1 Inhibition Potentiates the Effects of Nab-Paclitaxel-Gemcitabine and Modulates the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma.
Ahmad IM; Dafferner AJ; O'Connell KA; Mehla K; Britigan BE; Hollingsworth MA; Abdalla MY
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34066839
[TBL] [Abstract][Full Text] [Related]
19. Extracellular Matrix Composition Modulates the Responsiveness of Differentiated and Stem Pancreatic Cancer Cells to Lipophilic Derivate of Gemcitabine.
Forciniti S; Dalla Pozza E; Greco MR; Amaral Carvalho TM; Rolando B; Ambrosini G; Carmona-Carmona CA; Pacchiana R; Di Molfetta D; Donadelli M; Arpicco S; Palmieri M; Reshkin SJ; Dando I; Cardone RA
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375106
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches.
Truong LH; Pauklin S
Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
